NASDAQ:ATRS - Antares Pharma Stock Price, News, & Analysis

-0.04 (-1.31 %)
(As of 06/20/2019 03:16 AM ET)
Today's Range
Now: $3.01
50-Day Range
MA: $2.88
52-Week Range
Now: $3.01
Volume960,330 shs
Average Volume898,893 shs
Market Capitalization$489.49 million
P/E RatioN/A
Dividend YieldN/A
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:ATRS



Sales & Book Value

Annual Sales$63.55 million
Book Value$0.25 per share


Net Income$-6,510,000.00


Market Cap$489.49 million
Next Earnings Date8/6/2019 (Estimated)

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings data on Thursday, May, 2nd. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The specialty pharmaceutical company earned $23.29 million during the quarter, compared to analyst estimates of $17.46 million. Antares Pharma had a negative net margin of 7.91% and a negative return on equity of 17.94%. View Antares Pharma's Earnings History.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Antares Pharma.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma updated its FY 2019 earnings guidance on Thursday, May, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $95-105 million, compared to the consensus revenue estimate of $99.47 million.

What price target have analysts set for ATRS?

5 Wall Street analysts have issued twelve-month target prices for Antares Pharma's stock. Their forecasts range from $1.99 to $8.00. On average, they expect Antares Pharma's stock price to reach $4.8280 in the next year. This suggests a possible upside of 60.4% from the stock's current price. View Analyst Price Targets for Antares Pharma.

What is the consensus analysts' recommendation for Antares Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.

Has Antares Pharma been receiving favorable news coverage?

Media headlines about ATRS stock have trended neutral recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Antares Pharma earned a news impact score of 0.2 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Antares Pharma.

Are investors shorting Antares Pharma?

Antares Pharma saw a drop in short interest in May. As of May 31st, there was short interest totalling 8,062,300 shares, a drop of 9.1% from the April 30th total of 8,873,300 shares. Based on an average daily volume of 919,000 shares, the days-to-cover ratio is currently 8.8 days. Approximately 5.7% of the shares of the company are sold short. View Antares Pharma's Current Options Chain.

Who are some of Antares Pharma's key competitors?

What other stocks do shareholders of Antares Pharma own?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
  • Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (2.11%), Mycio Wealth Partners LLC (1.01%), Fosun International Ltd (0.36%), Perkins Capital Management Inc. (0.27%), Monarch Partners Asset Management LLC (0.07%) and Mercer Global Advisors Inc. ADV (0.03%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Which institutional investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Mycio Wealth Partners LLC, FMR LLC, Quantitative Systematic Strategies LLC and SG Americas Securities LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Which institutional investors are buying Antares Pharma stock?

ATRS stock was bought by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, Fosun International Ltd, Mercer Global Advisors Inc. ADV, Perkins Capital Management Inc., BNP Paribas Arbitrage SA, Searle & CO., Enterprise Bank & Trust Co and Alpine Woods Capital Investors LLC. View Insider Buying and Selling for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $3.01.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $489.49 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma.

What is Antares Pharma's official website?

The official website for Antares Pharma is

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]

MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel